Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF
PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING, INSULIN FOR DIABETES
News
Cambridge, UK, 13th April 2022: Mursla, a novel multi-omics exosome characterisation company, is pleased to present its novel nanochip-based technology, as detailed in the pre-print* ‘An electro-optical bead-nanochip technology for the ultrasensitive and multi-dimensional detection of small extracellular vesicles and their markers’, published today. This technology is part of Mursla’s ExoPheno™ platform.
Key features of the technology include:
AbbVie and We Are Pioneer Group launch Golden Ticket programme to help UK life science start-ups accelerate the delivery of life-changing innovations to patients
● Programme designed to help promising start-ups commercialise drug discovery and provide access to much-needed laboratory space
● 2021 was the highest year on record for investments into UK biotech and life sciences companies – who raised £4.5 billion
● Move demonstrates AbbVie’s and WAPG’s commitment to investing in the UK’s world-class life sciences sector
AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.
Jennifer has more than 16 years’ commercial leadership experience in the diagnostics and life sciences industries
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has appointed Jennifer Murphy as Senior Vice President of Global Commercial Operations. In her new role, Jennifer will be responsible for building and growing the global commercial programs for all BioIVT’s product lines and services.
Boom in start-ups and spin-outs drives growth for UK life sciences as investment almost doubles
● New report shows number of UK life science start-ups in 2016-20 increased by 24% on the previous reporting period to a total of 681, at almost double the rate of ten years ago.
● £20 billion worth of capital is looking to invest in UK life science real estate.
● Total investment in the UK life sciences sector reached a record £4.5 billion in 2021, nearly double the £2.8 billion invested in 2020 (BioIndustry Association).
Boyds, the global drug development consultancy, has reported another strong year of growth, with an increase in excess of 20 percent year-on-year in annual revenue in the wake of increased demand for its specialist expertise across the UK, US, and Europe.
Since the opening of Boyds’ US office in Pennsylvania last year, headed by Katy Rudnick, the company has recorded significant growth in US revenue, which now accounts for approximately 30 percent of its total revenue.
SOMERSET, N.J. – April 6, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
AMSBIO announce the addition of several new products to its growing range of magnetic bead based nucleic acid extraction kits for pathogen detection.
The MagSi-NA Pathogens MSP (Multiple Sample Pooling) kit sets a new benchmark for automated isolation of nucleic acids (RNA and DNA) from respiratory samples.